Literature DB >> 2942104

Ciprofloxacin in the treatment of pneumonia.

J A Ernst, E R Sy, H Colon-Lucca, N Sandhu, T Rallos, V Lorian.   

Abstract

The use of ciprofloxacin as the sole agent in the treatment of 25 patients with pneumonias caused by susceptible organisms resulted in rapid cure. No side effects, superinfections, or recurrences were observed.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2942104      PMCID： PMC180504          DOI： 10.1128/AAC.29.6.1088

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  4 in total

1.  Ciprofloxacin penetration into extravascular spaces in a rabbit model.

Authors:  K L Nichol; L R Peterson; C E Fasching; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

2.  In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.

Authors:  G M Eliopoulos; A Gardella; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

3.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

4.  Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.

Authors:  M A Gonzalez; F Uribe; S D Moisen; A P Fuster; A Selen; P G Welling; B Painter
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191
  4 in total
  6 in total

1.  Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections.

Authors:  H Lode; R Wiley; G Höffken; J Wagner; K Borner
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

2.  Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin.

Authors:  A Torres; T T Bauer; C León-Gil; F Castillo; F Alvarez-Lerma; A Martínez-Pellús; S R Leal-Noval; P Nadal; M Palomar; J Blanquer; F Ros
Journal:  Thorax       Date:  2000-12       Impact factor: 9.139

3.  Comparative efficacies of ciprofloxacin, amoxicillin, amoxicillin-clavulanic acid, and cefaclor against experimental Streptococcus pneumoniae respiratory infections in mice.

Authors:  J Gisby; B J Wightman; A S Beale
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

Review 4.  Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.

Authors:  J P Thys; F Jacobs; B Byl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 5.  Clinical utility of new quinolones in treatment of osteomyelitis and lower respiratory tract infections.

Authors:  A S Bayer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

Review 6.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.